You are here: Industry Insights > Market News > Sanofi to produce 100 million Pfizer/BioNTech vaccine doses: CEO

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Sanofi to produce 100 million Pfizer/BioNTech vaccine doses: CEO

expresspharmaJanuary 27, 2021

Tag: COVID-19 Vaccine , Sanofi , Pfizer , BioNTech

Favorites

Sanofi will produce more than 100 million doses of the COVID-19 vaccine developed by its competitors Pfizer and BioNTech by the end of the year, said Paul Hudson, CEO of Sanofi in an interview with Le Figaro newspaper.

As Sanofi and GlaxoSmithKline have delayed the launch of their shot to late 2021, the French company decided to approach Pfizer “in order to be helpful as of now”, Hudson said, adding that an agreement with the US company had been reached.

Previous:Sheffield University gets £1.6 mn grant from Medical Research Council

Next:Hikma intends to acquire assets in Egypt, Tunisia

InnoCare Sets up Specific Environment Management Target in its Fifth ESG Report

PharmaSourcesApril 28, 2024

InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases.

Touchlight Awarded Grant Extension to Further Develop DNA-Enabled Biobatteries with U.S. Office for Naval Research and UK Defence Science & Technology Laboratory

Biotech NewswireApril 26, 2024

Study Results of Orelabrutinib in Patients with ITP Published by the American Journal of Hematology

PharmaSourcesApril 18, 2024

Sanofi to produce 100 million Pfizer/BioNTech vaccine doses: CEO | Pharmasources.com

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

PharmaSourcesApril 17, 2024

Company is targeting pancreatic cancer pain with advanced nerve detection and treatment technology

Sanofi to produce 100 million Pfizer/BioNTech vaccine doses: CEO

Related News

InnoCare Sets up Specific Environment Management Target in its Fifth ESG Report

Touchlight Awarded Grant Extension to Further Develop DNA-Enabled Biobatteries with U.S. Office for Naval Research and UK Defence Science & Technology Laboratory

Study Results of Orelabrutinib in Patients with ITP Published by the American Journal of Hematology

Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment Technology

You may like